Pulmonary vasoreactivity and vasoactive mediators in children with pulmonary hypertension;Pulmonale gefassreagibilitat und vasoaktive mediatoren bei kindern mit pulmonaler hypertension

Zeitschrift fur Kardiologie

Volumn 89, Issue 11, 2000, Pages 1000-1008

  Gorenflo, M ^a   Bettendorf, M ^b   Brockmeier, K ^a   Ulmer, H E ^a  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^b Dept Endocrinology ^*

Author keywords

Children; Congenital heart disease; Nitric oxide; Pulmonary hypertension

Indexed keywords

CYCLIC AMP; CYCLIC GMP; ENDOTHELIN 1; ILOPROST; NITRIC OXIDE; OXYGEN; PROSTACYCLIN; PROSTANOID;

ADOLESCENT; ARTICLE; BLOOD SAMPLING; BLOOD VESSEL REACTIVITY; CHILD; CLINICAL ARTICLE; CONGENITAL HEART DISEASE; DISEASE ASSOCIATION; DRUG EFFECT; HUMAN; INFANT; LUNG BLOOD VESSEL; LUNG HEMODYNAMICS; LUNG PERFUSION; LUNG RESISTANCE; MEDIATOR RELEASE; NEBULIZATION; PULMONARY HYPERTENSION; VASODILATATION;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; CYCLIC AMP; CYCLIC GMP; ENDOTHELIN-1; FEMALE; HUMANS; HYPERTENSION, PULMONARY; ILOPROST; INFANT; MALE; NITRIC OXIDE; OXYGEN INHALATION THERAPY; RETROSPECTIVE STUDIES; VASODILATION;

EID: 0033667256     PISSN: 03005860     EISSN: None     Source Type: Journal    
DOI: 10.1007/s003920070151     Document Type: Article

References (27)

1. Combined effects of nitric oxide and oxygen during acute pulmonary vasodilator testing
2. Pulmonary hypertension after operations for congenital heart disease: Analysis of risk factors and management
3. Dynamic changes of endothelin-1, nitric oxide, and cyclic GMP in patients with congenital heart disease
4. Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin
5. Endothelin-1 in the lungs of patients with primary pulmonary hypertension
6. Invasive diagnostic and therapeutic techniques. Part 1. Cardiac catheterization
7. Role of pharmacologic tests in the treatment of primary pulmonary hypertension
8. Primary pulmonary hypertension. Insights into pathogenesis from epidemiology
9. Does inhaled nitric oxide suppress endogenous nitric oxide production?
10. Oxygen mediated pulmonary vasodilation and plasma levels of endothelin-1, atrial natriuretic peptide and cyclic GMP in patients with left-to-right shunt and pulmonary hypertension
11. Pulmonary vascular disease in secundum atrial septal defect in childhood
12. Long term intravenous prostaglandin (epoprostenol or iloprost) for treatment of severe pulmonary hypertension
13. Additive effect of beraprost on pulmonary vasodilation by inhaled nitric oxide in children with pulmonary hypertension
14. Inhaled nitric oxide as a therapy for pulmonary hypertension after operations for congenital heart defects
15. The estimation of oxygen consumption
16. Continuous infusion of epoprostenol improves the net balance between pulmonary endothelin-1 clearance and release in primary pulmonary hypertension
17. Endothelins
18. Guidelines for the safe administration of inhaled nitric oxide
19. 2, prostacyclin and other eicosanoids in the cardiovascular system
20. Inhaled nitric oxide in congenital heart disease
21. Primary pulmonary hypertension
22. Nitric oxide, oxygen and prostacyclin in children with pulmonary hypertension
23. Cardiac catheterization: Hemodynamic measurements
24. Defects of the atrial septum including atrioventricular septal defects
25. Kinetics of methaemoglobin and serum nitrogen oxide production during inhalation of nitric oxide in volunteers
26. Response to inhaled nitric oxide (NO) is not associated with changes of plasma cGMP levels in patients with acute lung injury